New strategies for haploidentical transplantation

Oevermann, Lena; Handgretinger, Rupert

doi:10.1038/pr.2011.60

Cited by 28 publications

(21 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PTLD occurred more frequently than would be expected from a T replete allogeneic transplant 31 and from a CD34 1 cell-selected graft. 32 Because 2 of the first 3 patients had EBV reactivation and 1 had PTLD in recipient cells, we reasoned that the reduced-intensity conditioning was not eradicating EBV-containing host B cells that could transform to PTLD. 33 We added rituximab to the conditioning regimen on day 21 for patients who were EBV seropositive before transplant.…”

Section: Discussionmentioning

confidence: 99%

Alternative donor hematopoietic stem cell transplantation for sickle cell disease

Gilman

Eckrich

Epstein³

et al. 2017

Blood Advances

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Alternative donor hematopoietic stem cell transplantation for sickle cell disease

Gilman

Eckrich

Epstein³

et al. 2017

Blood Advances

View full text Add to dashboard Cite

show abstract

“…In adults, the use of partially T‐cell‐depleted haploidentical marrow using anti‐CD3 combined with intensive total body irradiation achieved similar results . With the establishment and availability of high‐quality monoclonal antibodies (MoAbs) developed for characterization of T‐cell subsets and hematopoietic (CD34+) progenitors, more effective positive and negative cell selection methods were established over the past two decades . Different cell selection systems were developed such as the Ceprate SC immunoaffinity column (CellPro, Bothell, WA), the Isolex 300i magnetic cell selection system (Nexell/Baxter, Irvine, CA), and the CliniMACS CD34 reagent system (Miltenyi, Cambridge, MA), Dynabeads (Dynal/Invitrogen, Carlsbad, CA) for immunopanning of target cells, and flow cytometric cell sorting techniques .…”

Section: Comparison Of Previously Used Cell Selection Methodsmentioning

confidence: 99%

How do I perform hematopoietic progenitor cell selection?

et al. 2016

View full text Add to dashboard Cite

Graft-versus-host disease remains the most important source of morbidity and mortality associated with allogeneic stem cell transplantation. The implementation of hematopoietic progenitor cell (HPC) selection is employed by some stem cell processing facilities to mitigate this complication. Current cell selection methods include reducing the number of unwanted T-cell (negative selection) and/or enriching CD34+ hematopoietic stem/progenitors (positive selection) using immunomagnetic beads subjected to magnetic fields within columns to separate out targeted cells. Unwanted side effects of cell selection as a result of T cell reduction are primary graft failure, increased infection rates, delayed immune reconstitution, possible disease relapse and post-transplant lymphoproliferative disease. The Miltenyi CliniMACS Cell Isolation System is the only device currently approved for clinical use by the FDA. It uses magnetic microbeads conjugated with a high affinity anti-CD34 monoclonal antibody capable of binding to HPCs in bone marrow, peripheral blood or umbilical cord blood products. The system results in significantly improved CD34+ cell recoveries (50–100%) and consistent three log CD3+ T cell reductions compared to previous generations of CD34+ cell selection procedures. In this article, the CliniMACS procedure is described in greater detail and the authors provide useful insight into modifications of the system. Successful implementation of cell selection procedures can have a significant positive clinical effect by greatly increasing the pool of donors for recipients requiring transplants. However, before a program implements cell selection techniques, it is important to consider the time and financial resources required to properly and safely perform these procedures.

show abstract

“…Using this approach, mature, alloreactive NK cells were available much earlier than when using CD34 + stem cell grafts as in this instance the alloreactive NK cells need to be newly generated . Lena Oevermann from Rupert Handgretinger 's group in Tübingen (Germany) emphasized the importance of including KIR genotyping in the donor selection algorithm and, for transplant pediatric ALL patients, using grafts from donors having a high KIR haplotype B‐content score since each person possesses an individual pattern of KIR genes assigned to either haplotype A or B, the latter harboring at least one activating KIR receptor . Ulrike Koehl (Hanover, Germany) reported on clinical trials conducted by a German/Swiss consortium in which allogeneic, unstimulated or IL‐2‐stimulated NK cells were employed for the treatment of patients with high‐risk tumours or leukaemia .…”

Section: Nk Cells and Cancermentioning

confidence: 99%

NK cells – Versatile tools for viral defense and cancer treatment

2013

View full text Add to dashboard Cite

About 150 NK cell researchers met at the German Cancer Research Center (DKFZ) in Heidelberg, Germany from 26–28 September 2012 for the Natural Killer Cell Symposium which was organized by the NK cell study group of the German Society for Immunology (DGfI) and sponsored by the European Journal of Immunology (EJI), the European Federation of Immunological Societies (EFIS) and the DGfI. The meeting was a forum for the discussion of the function and regulation of these fascinating innate immune cells and the opportunities for the transfer of this knowledge to cancer immunotherapy.

show abstract

New strategies for haploidentical transplantation

Cited by 28 publications

References 85 publications

Alternative donor hematopoietic stem cell transplantation for sickle cell disease

Alternative donor hematopoietic stem cell transplantation for sickle cell disease

How do I perform hematopoietic progenitor cell selection?

NK cells – Versatile tools for viral defense and cancer treatment

Contact Info

Product

Resources

About